AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19946861 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAS-cog
Number of subjects: 1566
Study 19946861 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMCOG
Number of subjects: 1566
Study 19946861 — intervention group
Group type: EXPERIMENTAL
Intervention: MMSE
Number of subjects: 1566
Study 18940117 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe vera gel
Number of subjects: 34
Study 18940117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 16180951 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-oriented willed-movement (POWM) therapy
Number of subjects: 47
Study 16180951 — intervention group
Group type: COMPARATOR
Intervention: Neurodevelopmental treatment (NDT)
Number of subjects: 47
Study 12844392 — intervention group
Group type: EXPERIMENTAL
Intervention: Linoleic acid added to ice creams
Number of subjects: 24
Study 12844392 — intervention group
Group type: COMPARATOR
Intervention: Placebo (ice creams without linoleic acid)
Number of subjects: 24
Study 11305734 — intervention group
Group type: EXPERIMENTAL
Intervention: U‐73122 (phospholipase C inhibitor)
Number of subjects: 15
Study 11305734 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy volunteers)
Number of subjects: 15
Study 8831164 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative individual performance feedback
Number of subjects: 0
Study 8831164 — intervention group
Group type: COMPARATOR
Intervention: No negative individual performance feedback
Number of subjects: 0
Study 1564708 — intervention group
Group type: EXPERIMENTAL
Intervention: First menstrual cycle after IVF
Number of subjects: 35
Study 1564708 — intervention group
Group type: EXPERIMENTAL
Intervention: Second menstrual cycle after IVF
Number of subjects: 35
Study 1564708 — intervention group
Group type: EXPERIMENTAL
Intervention: Third menstrual cycle after IVF
Number of subjects: 35
Study 1564708 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall ovulatory cycles
Number of subjects: 35
Study 1564708 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovulatory cycles with luteal phase deficiencies
Number of subjects: 35
Study 4075795 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 micrograms Sulprostone
Number of subjects: 200
Study 4075795 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 micrograms Sulprostone
Number of subjects: 200
Study 29723443 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 18
Study 29723443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 29132804 — intervention group
Group type: EXPERIMENTAL
Intervention: Lighted Stylet
Number of subjects: 62
Study 29132804 — intervention group
Group type: COMPARATOR
Intervention: GlideScope
Number of subjects: 62
Study 26652037 — intervention group
Group type: EXPERIMENTAL
Intervention: β-alanine supplementation
Number of subjects: 14
Study 26652037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 25131977 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic, daily, implant-based, multiparameter telemonitoring in addition to standard care
Number of subjects: 716
Study 25131977 — intervention group
Group type: COMPARATOR
Intervention: Standard care without telemonitoring
Number of subjects: 716
Study 25131977 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring group
Number of subjects: 716
Study 25131977 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 716
Study 22241570 — intervention group
Group type: EXPERIMENTAL
Intervention: Gravity-assisted drainage position (20° head-down tilt)
Number of subjects: 20
Study 22241570 — intervention group
Group type: COMPARATOR
Intervention: Modified drainage position (no head-down tilt)
Number of subjects: 20
Study 19841925 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine (catheter group)
Number of subjects: 70
Study 19841925 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (single-shot group)
Number of subjects: 70
Study 18490003 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular depression features
Number of subjects: 0
Study 16146546 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 186
Study 16146546 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 186
Study 14519754 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 microg daily)
Number of subjects: 1312
Study 10820295 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic diagnostic methods (visual postural analysis, pain description, plain static erect x-ray, leg length discrepancy, neurologic tests, motion palpation, static palpation, orthopedic tests)
Number of subjects: 38
Study 8873109 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose UL ECT (three times the threshold)
Number of subjects: 0
Study 8873109 — intervention group
Group type: COMPARATOR
Intervention: Low-dose UL ECT (threshold)
Number of subjects: 0
Study 1505422 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily brushing (96% reported brushing daily)
Number of subjects: 243
Study 1505422 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical examination using WHO criteria
Number of subjects: 243
Study 1505422 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental visits (39% had visited a dentist before, 16% at least once a year)
Number of subjects: 243
Study 3965236 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pentoxifylline (400 mg)
Number of subjects: 10
Study 3965236 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pentoxifylline (200 mg)
Number of subjects: 10
Study 3965236 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and intravenous dosing
Number of subjects: 10
Study 31650861 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplement adherence
Number of subjects: 158
Study 31409380 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS-focused treatment program
Number of subjects: 0
Study 31409380 — intervention group
Group type: COMPARATOR
Intervention: Standard medical and physical therapy care
Number of subjects: 0
Study 30404504 — intervention group
Group type: EXPERIMENTAL
Intervention: 20kHz ultrasound stimulus presented continuously for 20 minutes at 84dB SPL, 15dB below detection threshold
Number of subjects: 0
Study 30404504 — intervention group
Group type: COMPARATOR
Intervention: Sham presentation (control group)
Number of subjects: 0
Study 30404504 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectation of ultrasound presence (nocebo response)
Number of subjects: 0
Study 27853357 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth management system with adherence sensor and mobile app (4 participants)
Number of subjects: 7
Study 27853357 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth management system with adherence sensor (3 participants)
Number of subjects: 7
Study 23982929 — intervention group
Group type: EXPERIMENTAL
Intervention: AG/GG genotype of rs5995355 in NCF4
Number of subjects: 2019
Study 22751874 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (vitamin D3) 2000 IU daily
Number of subjects: 38
Study 22751874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 20685683 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of forced-air and a circulating-water mattress (CWM)
Number of subjects: 50
Study 20685683 — intervention group
Group type: COMPARATOR
Intervention: Circulating-water garment (CWG)
Number of subjects: 50
Study 17389290 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized alerts with pharmacist-mediated academic detailing
Number of subjects: 853
Study 18378968 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonfils intubation fibrescope (BIF)
Number of subjects: 76
Study 18378968 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy (Macintosh blade)
Number of subjects: 76
Study 15611465 — intervention group
Group type: EXPERIMENTAL
Intervention: Total extraperitoneal inguinal hernioplasty with mesh fixation using staples
Number of subjects: 170
Study 15611465 — intervention group
Group type: COMPARATOR
Intervention: Total extraperitoneal inguinal hernioplasty without mesh fixation
Number of subjects: 170
Study 15887713 — intervention group
Group type: EXPERIMENTAL
Intervention: ICCE with anterior chamber intraocular lens (AC IOL)
Number of subjects: 502
Study 15887713 — intervention group
Group type: COMPARATOR
Intervention: ICCE with aphakic spectacles (AS)
Number of subjects: 502
Study 15887713 — intervention group
Group type: COMPARATOR
Intervention: Comparison between ICCE/AC IOL and ICCE/AS
Number of subjects: 502
Study 15887713 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 502
Study 8985273 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 211
Study 8985273 — intervention group
Group type: COMPARATOR
Intervention: Griseofulvin
Number of subjects: 211
Study 8107548 — intervention group
Group type: EXPERIMENTAL
Intervention: Run-only training (N = 6)
Number of subjects: 11
Study 8107548 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle/run training (N = 5)
Number of subjects: 11
Study 3313101 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine with steroids
Number of subjects: 0
Study 3313101 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine without steroids
Number of subjects: 0
Study 3313101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31274608 — intervention group
Group type: EXPERIMENTAL
Intervention: Parotid gland massage
Number of subjects: 100
Study 31274608 — intervention group
Group type: COMPARATOR
Intervention: Nonmassage group
Number of subjects: 100
Study 28831535 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group (individuals at moderate-to-high risk invited for assessment)
Number of subjects: 1912392
Study 28831535 — intervention group
Group type: COMPARATOR
Intervention: No-screening group (retrospectively constructed control group)
Number of subjects: 1912392
Study 26248828 — intervention group
Group type: COMPARATOR
Intervention: Continuing antibiotics group (CAG)
Number of subjects: 0
Study 26248828 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuing antibiotics group (DAG)
Number of subjects: 0
Study 23799356 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Therapy (HT)
Number of subjects: 16347
Study 23799356 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and Vitamin D (CaD)
Number of subjects: 16347
Study 23799356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16347
Study 22728026 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 150 mg/m(2) qw 3/4
Number of subjects: 302
Study 22728026 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 100 mg/m(2) qw 3/4
Number of subjects: 302
Study 22728026 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 300 mg/m(2) q3w
Number of subjects: 302
Study 22728026 — intervention group
Group type: COMPARATOR
Intervention: docetaxel 100 mg/m(2) q3w
Number of subjects: 302
Study 22728026 — intervention group
Group type: EXPERIMENTAL
Intervention: all nab-paclitaxel arms
Number of subjects: 302
Study 19553282 — intervention group
Group type: COMPARATOR
Intervention: Best Practice (BP) only
Number of subjects: 360
Study 19553282 — intervention group
Group type: COMPARATOR
Intervention: Best Practice plus ultrasound feedback (BP+US)
Number of subjects: 360
Study 19553282 — intervention group
Group type: COMPARATOR
Intervention: Motivational Interviewing‐based counseling plus ultrasound feedback (MI+US)
Number of subjects: 360
Study 17684468 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium picolinate and biotin combination (600 microg chromium as chromium picolinate and 2 mg biotin)
Number of subjects: 348
Study 17684468 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium picolinate and biotin combination
Number of subjects: 348
Study 17684468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 348
Study 15963313 — intervention group
Group type: EXPERIMENTAL
Intervention: People with Arthritis Can Exercise program
Number of subjects: 347
Study 15963313 — intervention group
Group type: COMPARATOR
Intervention: Noncompleters of the program
Number of subjects: 347
Study 11967494 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of 0.01% recombinant human platelet-derived growth factor gel
Number of subjects: 21
Study 11967494 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 21
Study 9577944 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary (IC) enalaprilat (0.05 mg/min for 15 minutes)
Number of subjects: 20
Study 9577944 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual (SL) captopril (25 mg)
Number of subjects: 20
Study 8588830 — intervention group
Group type: EXPERIMENTAL
Intervention: Syncroner (2 puffs of 2 mg 4 times a day for two weeks)
Number of subjects: 144
Study 8588830 — intervention group
Group type: COMPARATOR
Intervention: Standard mouthpiece (2 puffs of 2 mg 4 times a day for two weeks)
Number of subjects: 144
Study 8588830 — intervention group
Group type: EXPERIMENTAL
Intervention: Syncroner
Number of subjects: 144
Study 2501133 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 micrograms enprostil
Number of subjects: 12
Study 2501133 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 micrograms enprostil
Number of subjects: 12
Study 2501133 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 micrograms enprostil
Number of subjects: 12
Study 2501133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 46712 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone-releasing devices (various doses)
Number of subjects: 402
Study 46712 — intervention group
Group type: COMPARATOR
Intervention: Placebo (empty device)
Number of subjects: 402
Study 31038562 — intervention group
Group type: EXPERIMENTAL
Intervention: sitagliptin 100 mg per day + metformin + insulin glargine
Number of subjects: 70
Study 31038562 — intervention group
Group type: COMPARATOR
Intervention: voglibose 0.2 mg three times daily + metformin + insulin glargine
Number of subjects: 70
Study 28318744 — intervention group
Group type: EXPERIMENTAL
Intervention: CPRA >80%
Number of subjects: 3855
Study 28318744 — intervention group
Group type: COMPARATOR
Intervention: CPRA ≤10%
Number of subjects: 3855
Study 25545757 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glutamic acid
Number of subjects: 250
Study 25545757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 23915518 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan
Number of subjects: 30
Study 23915518 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 30
Study 21277566 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (20 mg)
Number of subjects: 18
Study 21277566 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (60 mg)
Number of subjects: 18
Study 21277566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 19901314 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary outcome
Number of subjects: 110
Study 19901314 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcome
Number of subjects: 110
Study 16703733 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 64
Study 16703733 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil 50 mg
Number of subjects: 64
Study 16703733 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil dosing instructions
Number of subjects: 64
Study 16703733 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil dosing instructions
Number of subjects: 64
Study 15149872 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) and Vitamin C and E (VCE)
Number of subjects: 80
Study 11562616 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-demand feeding protocol
Number of subjects: 81
Study 11562616 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 81
Study 9197298 — intervention group
Group type: COMPARATOR
Intervention: Thiopental/nitrous oxide
Number of subjects: 66
Study 9197298 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 66
Study 9197298 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 66
Study 9197298 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 66
Study 8181124 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 227
Study 8181124 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy
Number of subjects: 227
Study 2884114 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam mesylate 100 mg under fed conditions
Number of subjects: 8
Study 2884114 — intervention group
Group type: COMPARATOR
Intervention: Fenoldopam mesylate 100 mg under fasting conditions
Number of subjects: 8
Study 2884114 — intervention group
Group type: EXPERIMENTAL
Intervention: SK&F 87782 under fed conditions
Number of subjects: 8
Study 2884114 — intervention group
Group type: COMPARATOR
Intervention: SK&F 87782 under fasting conditions
Number of subjects: 8
Study 2884114 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam 24-hour excretion under fed conditions
Number of subjects: 8
Study 2884114 — intervention group
Group type: EXPERIMENTAL
Intervention: SK&F 87782 24-hour excretion under fed conditions
Number of subjects: 8
Study 31284794 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06438179/GP1111 (PF-SZ-IFX)
Number of subjects: 650
Study 31284794 — intervention group
Group type: COMPARATOR
Intervention: Reference infliximab (ref-IFX-EU)
Number of subjects: 650
Study 28874948 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic prescriptions (E-prescriptions)
Number of subjects: 2883
Study 28874948 — intervention group
Group type: COMPARATOR
Intervention: Handwritten prescriptions (HW)
Number of subjects: 2883
Study 26892359 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam 1 mg/kg (MS)
Number of subjects: 18
Study 26892359 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PS)
Number of subjects: 18
Study 24261665 — intervention group
Group type: EXPERIMENTAL
Intervention: GNUMAP-bs alignment algorithm
Number of subjects: 0
Study 24261665 — intervention group
Group type: COMPARATOR
Intervention: Other commonly-used bisulfite alignment methods
Number of subjects: 0
Study 22123804 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (0.5 mg/kg every 6 hours for 72 hours, 0.5 mg/kg every 12 hours on days 4 through 6, and 0.5 mg/kg/d on days 7 through 10)
Number of subjects: 83
Study 22123804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 22123804 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone
Number of subjects: 83
Study 19389421 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=16)
Number of subjects: 33
Study 19389421 — intervention group
Group type: COMPARATOR
Intervention: Active comparison group (n=17)
Number of subjects: 33
Study 16368364 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary therapy (preoperative guided imagery training with gentle touch or light massage and postoperative music with gentle touch or light massage and guided imagery)
Number of subjects: 104
Study 16368364 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 104
Study 15516551 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal-contact psychotherapy
Number of subjects: 216
Study 15516551 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 216
Study 10676792 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical pachymetry
Number of subjects: 1717
Study 10676792 — intervention group
Group type: EXPERIMENTAL
Intervention: Slitlamp‐mounted ultrasound
Number of subjects: 1717
Study 10676792 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld ultrasound
Number of subjects: 1717
Study 9770938 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen-alginate wound dressing
Number of subjects: 20
Study 9770938 — intervention group
Group type: COMPARATOR
Intervention: Soaks and daily dressing changes
Number of subjects: 20
Study 2901120 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpidem 50 mg
Number of subjects: 188
Study 2901120 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpidem 75 mg
Number of subjects: 188
Study 2901120 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpidem 50-150 mg/day for 3-4 weeks
Number of subjects: 188
Study 2901120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study 30852837 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone (0.03 mg/kg)
Number of subjects: 91
Study 30852837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 28719554 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical treatment with a figure‐of‐eight harness
Number of subjects: 117
Study 28719554 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment with anteroinferior plate osteosynthesis
Number of subjects: 117
Study 25492411 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 µg corifollitropin alfa
Number of subjects: 79
Study 25492411 — intervention group
Group type: COMPARATOR
Intervention: 450 IU follitropin beta
Number of subjects: 79
Study 23970136 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (multidisciplinary care, lifestyle program, aerobic and resistance exercise training for 12 months)
Number of subjects: 83
Study 23970136 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 83
Study 22137076 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg before PCI and for 5 days after PCI)
Number of subjects: 173
Study 22137076 — intervention group
Group type: COMPARATOR
Intervention: Control (10 mg daily after PCI)
Number of subjects: 173
Study 22137076 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin group
Number of subjects: 173
Study 22137076 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 173
Study 18990504 — intervention group
Group type: EXPERIMENTAL
Intervention: AS+RT plus four cycles of TEE (paclitaxel, estramustine, etoposide)
Number of subjects: 397
Study 18990504 — intervention group
Group type: COMPARATOR
Intervention: AS+RT
Number of subjects: 397